Eagan, Minnesota--(Newsfile Corp. - September 14, 2023) - Dynatronics Corporation (NASDAQ: DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that the company will release financial results for its fourth quarter and fiscal year ended June 30, 2023 on Thursday, September 28, 2023 before the market opens.
The company will subsequently hold a conference call, consisting of prepared remarks by management, and a question-and-answer session with analysts, at 8:00 AM ET on Thursday, September 28, 2023, to review its fourth quarter and fiscal year 2023 results.
Interested persons may access the live conference call by dialing 800-319-4610 (U.S./Canada callers) or 604-638-5340 (international callers). It is recommended that participants call or login 10 minutes ahead of the scheduled start time to ensure proper connection. An audio replay will be available one hour after the live call until Midnight on October 5, 2023, by dialing 855-669-9658 (U.S./Canada callers) or 604-674-8052 (international callers), using replay access code 3039.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Contact:
Dynatronics Corporation
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
For additional information, please visit: www.dynatronics.com
Connect with Dynatronics on LinkedIn
Last Trade: | US$0.07 |
Daily Volume: | 0 |
Market Cap: | US$508K |
February 08, 2024 January 15, 2024 November 09, 2023 October 30, 2023 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load